Pancreatic cancer drug may hold promise for lung cancer as well, early study suggests — Live Feedhttps://www.live-feeds.com/feed/pancreatic-cancer-drug-may-hold-promise-for-lung-cancer-as-well-early-study-suggestsContinuously updated, source-cited coverage. FDA-approved pancreatic cancer drug shows promise for lung cancerhttps://www.live-feeds.com/feed/pancreatic-cancer-drug-may-hold-promise-for-lung-cancer-as-well-early-study-suggestshttps://www.live-feeds.com/feed/pancreatic-cancer-drug-may-hold-promise-for-lung-cancer-as-well-early-study-suggests#u58323Sat, 05 Sep 2026 17:38:50 +0000The FDA has approved daraxonrasib, marketed as Rasonque by Revolution Medicines, for the treatment of metastatic pancreatic cancer. Early clinical data now suggests the drug may also be effective for patients with metastatic non-small cell lung cancer, specifically those with RAS-mutant tumors. The New England Journal of Medicine recently published Phase 1/2 clinical data supporting this potential application. While initially developed for pancreatic cancer, these early results indicate the targeted therapy could expand its utility to treat other RAS-driven malignancies.Why it mattersRAS mutat